Lung Cancer

The FDA has accepted an application for afatinib (Gilotrif) as a treatment for patients with squamous cell non–small cell lung cancer following progression on chemotherapy.

Atezolizumab met the primary endpoint of objective response in PD-L1–positive patients with advanced non–small cell lung cancer in the phase II BIRCH trial.

Lee M. Krug, MD, associate attending physician, Division of Thoracic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses a phase I study examining intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion.

Amid continuing excitement over the potential for immunotherapies targeting the PD-1/PD-L1 pathway, two major questions have loomed over PD-L1 expression levels as a biomarker for this emerging new class of drugs.

Walter J. Curran, Jr., MD, Executive Director, Winship Cancer Institute of Emory University, Associate Vice President, Woodruff Health Sciences Center, discusses new developments in the delivery of radiation for patients with lung cancer.

Achieving true precision medicine with PD-1/PD-L1 agents in NSCLC will only come from biomarker-driven frontline regimens delivered to the right patients.

Pasi A. Jänne, MD, PhD, discuses the impact of gefitinib's reentry into the US market as a first-line treatment for patients with metastatic non–small cell lung cancer.

A new drug application has been submitted for rociletinib as a treatment for patients with EGFR T790M-positive metastatic non–small cell lung cancer following prior administration of an EGFR TKI.

Clinical trial designs are undergoing a dramatic transformation geared toward the discovery and validation of new predictive biomarkers.

Corey Langer, MD, discussed the therapeutic potential for anti-HER2 agents in non–small cell lung cancer in a presentation at the 2015 International Lung Cancer Congress.

A number of clinical trials are now assessing PD-1 and PD-L1 inhibitors in combination with chemotherapy, targeted therapies, and radiation therapy in an attempt to further improve outcomes for patients with non–small cell lung cancer.

Paul A. Bunn, Jr., MD, distinguished professor, University of Colorado, Lung Cancer: Giant of Cancer Care, discusses the need to study drug combinations in lung cancer.

Paul Bunn, MD, discussed the latest translational advances in NSCLC at the 2015 International Lung Cancer Congress.

Highly effective next-generation therapies are currently in development for patients with oncogene-driven non–small cell lung cancer, specifically those with alterations in EGFR, ALK, ROS1, NTRK, or a variety of other gene.

The FDA has granted a breakthrough therapy designation to the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib as a potential treatment for patients with BRAFV600E-mutant non-small cell lung cancer.